Markets:

Overview

News

Currencies

International

Treasuries

argenx SE - American Depositary Shares (NQ:ARGX)

861.83 -10.75 (-1.23%)

Streaming Delayed Price Updated: 9:42 AM EDT, Jul 31, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about argenx SE - American Depositary Shares

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

16 17 Next >

argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024

February 22, 2024

From argenx SE

Via GlobeNewswire

3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition ↗

February 21, 2024

Now could be the time to start looking into these biotech stocks as there are imminent approvals on their clinical trials.

Via InvestorPlace

argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy

February 20, 2024

From argenx SE

Via GlobeNewswire

5 medical stocks growing earnings by triple digits

February 06, 2024

There is a little known way to pick stocks like the pros do, and today's exercise points you to five high-probability winners in a sector that's quickly turning

Via MarketBeat

Topics Economy

Why Is Argenx (ARGX) Stock Down 25% Today? ↗

December 20, 2023

Following a late-stage clinical disappointment, Argenx has been forced back to the drawing board, thus cratering ARGX stock.

Via InvestorPlace

Argenx Dives On Autoimmune Therapy Failure ↗

December 20, 2023

A treatment for a skin-blistering condition failed to beat a placebo.

Via Investor's Business Daily

Stifel Maintains Buy Rating for argenx: Here's What You Need To Know ↗

December 18, 2023

Via Benzinga

New Hope For Patients With Chronic Autoimmune Conditions: Johnson & Johnson's Investigational Drug Meets Primary Goal In Two Studies ↗

February 05, 2024

Johnson & Johnson's nipocalimab shows promise in Phase 3 VIVACITY for gMG & Phase 2 DAHLIAS for SjD. FDA-approved Vyvgart Hytrulo for gMG.

Via Benzinga

Halozyme's Ambitious Five-Year Plan: Analysts Optimistic On Growth, Eyeing Market Expansion ↗

January 18, 2024

Explore Halozyme Therapeutics' promising financial outlook up to 2028. Discover revenue forecasts, earnings projections, and market insights.

Via Benzinga

argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis

January 18, 2024

From argenx SE

Via GlobeNewswire

5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond ↗

January 15, 2024

These five biotech companies could have a lot of room to run.

Via The Motley Fool

argenx Highlights 2024 Strategic Priorities

January 08, 2024

From argenx SE

Via GlobeNewswire

Here's How Much $1000 Invested In argenx 5 Years Ago Would Be Worth Today ↗

December 01, 2023

Via Benzinga

Analyst Ratings for argenx ↗

November 29, 2023

Via Benzinga

argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference

January 02, 2024

From argenx SE

Via GlobeNewswire

Stock Market Rally Is In Merry Mood Heading Into Christmas Weekend: Weekly Review ↗

December 22, 2023

Despite a Wednesday tumble, the major indexes are right at 2023 highs.

Via Investor's Business Daily

Argenx's Autoimmune Trial Stumble: Analysts Cut Price Targets, Warn of Risky Outcomes ↗

December 21, 2023

Wednesday, Argenx SE (NASDAQ: ARGX) released topline results from the ADDRESS Phase 3 study evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with pemphigus...

Via Benzinga

Immunovant Scores Much-Needed Win Following Argenx-Led Sell-off ↗

December 21, 2023

Immunovant reversed its fortunes Thursday following an Argenx-tied selloff Wednesday.

Via Investor's Business Daily

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

December 21, 2023

Via Benzinga

Amazon.com To Rally Over 38%? Here Are 10 Top Analyst Forecasts For Thursday ↗

December 21, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Why Steelcase Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

December 20, 2023

Steelcase Inc. (NYSE: SCS) shares moved higher during Wednesday's session following quarterly results.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

December 20, 2023

Via Benzinga

Why Is European Drugmaker Argenx Stock Sinking Today? ↗

December 20, 2023

Argenx SE (NASDAQ: ARGX) shares plunged after the company released topline results from the ADDRESS Phase 3 study evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in...

Via Benzinga

Why Aclarion Shares Are Trading Higher By Around 53%; Here Are 20 Stocks Moving Premarket ↗

December 20, 2023

Shares of Aclarion, Inc. (NASDAQ: ACON) shares rose sharply in pre-market trading after the company was granted U.S. patent #11844601 for "MR SPECTROSCOPY SYSTEM FOR DIAGNOSING PAINFUL AND NON-PAINFUL...

Via Benzinga

Topics Intellectual Property

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

December 20, 2023

Via Benzinga

FedEx Posts Downbeat Earnings, Joins Steelcase, argenx And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

December 20, 2023

U.S. stock futures were lower this morning, with the Dow Jones futures falling around 30 points on Wednesday.

Via Benzinga

Topics Stocks

argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus

December 20, 2023

From argenx SE

Via GlobeNewswire

Dow Jones Hits 2023 High, Nasdaq Slips; Tesla Cybertruck, Salesforce In Focus: Weekly Review ↗

December 01, 2023

Software earnings were strong, while the Fed is shifting toward rate cuts.

Via Investor's Business Daily

Topics Economy Stocks

Morgan Stanley Maintains Overweight Rating for argenx: Here's What You Need To Know ↗

November 30, 2023

Via Benzinga

Micron To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

November 29, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.